Idiopathic Pulmonary Fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD) characterized by abnormal epithelial cell behavior and excessive extracellular matrix deposition. Despite advances in understanding its molecular pathogenesis, the lack of early diagnostic biomarkers and effective targeted therapies remains a critical barrier. Metabolomics is the comprehensive profiling of low-molecular-weight metabolites and offers an emerging lens to unpack the complex metabolic reprogramming in IPF. This expert review discusses (1) current metabolomics approaches used in IPF research and (2) the key dysregulated metabolic pathways and their potential in improving diagnosis, prognostication, and treatment response monitoring. Furthermore, the review outlines the key metabolic signatures identified in non-IPF ILDs as well and compares their roles with those observed in IPF, thereby providing a broader perspective on shared and disease-specific metabolic alterations across the ILD spectrum.
AlnasserSM. The role of glutathione S-Transferases in human disease pathogenesis and their current inhibitors. Genes Dis, 2025; 12(4):101482; doi: 10.1016/j.gendis.2024.101482
2.
AshiqueS, De RubisG, SirohiE, et al.Short chain fatty acids: Fundamental mediators of the Gut-Lung axis and their involvement in pulmonary diseases. Chem Biol Interact, 2022; 368:110231; doi: 10.1016/j.cbi.2022.110231
3.
BanoeiMM, IupeI, BazazRD, et al.Metabolomic and metallomic profile differences between veterans and civilians with pulmonary sarcoidosis. Sci Rep, 2019; 9(1):19584; doi: 10.1038/s41598-019-56174-8
4.
BhattacharyyaP, MukherjeeS, MukherjeeA, et al.Etiological profile and evaluation of DPLD in Real-World: The perceived impression of the ILD treating doctors in India. J Assoc Chest Physicians, 2022; 10(2).
5.
CowardWR, SainiG, JenkinsG. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis, 2010; 4(6):367–388; doi: 10.1177/1753465810379801
6.
ChoudhuryP, BhattacharyaA, DasguptaS, et al.Identification of novel metabolic signatures potentially involved in the pathogenesis of COPD associated pulmonary hypertension. Metabolomics, 2021; 17(10):94; doi: 10.1007/s11306-021-01845-9
7.
ChoudhuryP, DasguptaS, KarA, et al.Bioinformatics analysis of hypoxia associated genes and inflammatory cytokine profiling in COPD-PH. Respir Med, 2024; 227:107658; doi: 10.1016/j.rmed.2024.107658
8.
DadrichM, NicolayNH, FlechsigP, et al.Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis. Oncoimmunology, 2016; 5(5):e1123366; doi: 10.1080/2162402X.2015.1123366
9.
DasguptaS, GhoshN, ChoudhuryP, et al.NMR metabolomic and microarray-based transcriptomic data integration identifies unique molecular signatures of hypersensitivity pneumonitis. Mol OMICS, 2022a;18(2):101–111; doi: 10.1039/d1mo00209k
10.
DasguptaS, SubramaniE, MitraI, et al.Discovery of novel metabolic signatures for early identification of women at risk of developing gestational hypertension. Metabolomics, 2023; 19(5):50; doi: 10.1007/s11306-023-02012-y
11.
DasguptaS. Identification and molecular modelling of potential drugs targeting the genes involved in the progression of lung cancer in patients with idiopathic pulmonary fibrosis. Gene Rep, 2024; 37(September):102067; doi: 10.1016/j.genrep.2024.102067
12.
DasguptaS. Unravelling genetic commonalities between idiopathic pulmonary fibrosis and gastroesophageal reflux disease: A bioinformatics exploration. Hum Gene, 2025:43; doi: 10.1016/j.humgen.2025.201375
13.
DasguptaS, BhattacharyaA, AbhijitRD, et al.Risk factors associated with mortality in hypersensitivity pneumonitis: A meta-analysis. Expert Rev Respir Med, 2022b;16(7):801–811; doi: 10.1080/17476348.2022.2100352
14.
FarkasL, GauldieJ, VoelkelNF, et al.Pulmonary hypertension and idiopathic pulmonary fibrosis: A tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol, 2011; 45(1):1–15; doi: 10.1165/rcmb.2010-0365TR
15.
FurukawaH, OkaS, ShimadaK, et al.Serum metabolomic profiles of rheumatoid arthritis patients with acute-onset diffuse interstitial lung disease. Biomark Insights, 2019; 14:1177271919870472; doi: 10.1177/1177271919870472
16.
FurukawaH, OkaS, ShimadaK, et al.Serum metabolomic profiling in rheumatoid arthritis patients with interstitial lung disease: A case-control study. Front Med (Lausanne), 2020; 7:599794; doi: 10.3389/fmed.2020.599794
GeamanuA, GuptaSV, BauerfeldC, et al.Metabolomics connects aberrant bioenergetic, transmethylation, and gut microbiota in sarcoidosis. Metabolomics, 2016; 12:35; doi: 10.1007/s11306-015-0932-2
19.
GreenR, BaldwinM, PooleyN, et al.the burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: A systematic evidence synthesis. Respir Res, 2024; 25(1):325; doi: 10.1186/s12931-024-02897-w
20.
HamanakaRB, MutluGM. Metabolic requirements of pulmonary fibrosis: Role of fibroblast metabolism. Febs J, 2021; 288(22):6331–6352; doi: 10.1111/febs.15693
21.
HamanakaRB, O’LearyEM, WittLJ, et al.Glutamine metabolism is required for collagen protein synthesis in lung fibroblasts. Am J Respir Cell Mol Biol, 2019; 61(5):597–606; doi: 10.1165/rcmb.2019-0008OC
22.
HukkanenJ, PelkonenO, RaunioH. Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: Possible role in susceptibility for ILD. Eur Respir J, 2001; 18(32 suppl):122s–126s.
23.
ImhofT, RosenblattK, PryymachukG, et al.Epithelial loss of mitochondrial oxidative phosphorylation leads to disturbed enamel and impaired dentin matrix formation in postnatal developed mouse incisor. Sci Rep, 2020; 10(1):22037; doi: 10.1038/s41598-020-77954-7
24.
KangYP, LeeSB, LeeJ-M, et al.Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis. J Proteome Res, 2016; 15(5):1717–1724; doi: 10.1021/acs.jproteome.6b00156
25.
KayEJ, KoulourasG, ZanivanS. Regulation of extracellular matrix production in activated fibroblasts: Roles of amino acid metabolism in collagen synthesis. Front Oncol, 2021; 11:719922; doi: 10.3389/fonc.2021.719922
26.
KhanT, DasguptaS, GhoshN, et al.Proteomics in idiopathic pulmonary fibrosis: The quest for biomarkers. Mol OMICS, 2021; 17(1):43–58; doi: 10.1039/d0mo00108b
27.
KimH-S, YooHJ, LeeKM, et al.Stearic acid attenuates profibrotic signalling in idiopathic pulmonary fibrosis. Respirology, 2021; 26(3):255–263; doi: 10.1111/resp.13949
28.
KottmannRM, KulkarniAA, SmolnyckiKA, et al.Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via PH-Dependent activation of transforming growth Factor-β. Am J Respir Crit Care Med, 2012; 186(8):740–751; doi: 10.1164/rccm.201201-0084OC
29.
LiS, LiC, SunW, et al.Spatially resolved metabolomics reveals metabolic heterogeneity among pulmonary fibrosis. J Mass Spectrom, 2025; 60(5):e5138; doi: 10.1002/jms.5138
30.
LiuM, ChengZJ, XueM, et al.The application of metabolomics toward idiopathic pulmonary fibrosis and potential metabolomic value of diverse samples in interstitial lung diseases. Precis Med Sci, 2023; 12(3):134–143; doi: 10.1002/prm2.12106
31.
LiuX, SuS, XiaL, et al.Lysophosphatidylcholine 14:0 alleviates lipopolysaccharide-induced acute lung injury via protecting alveolar epithelial barrier by activation of Nrf2/HO-1 pathway. J Inflamm Res, 2024; 17:10533–10546; doi: 10.2147/JIR.S495227
32.
López-RamírezC, Suarez ValdiviaL, Rodríguez PortalJA. Causes of pulmonary fibrosis in the elderly. Med Sci (Basel), 2018; 6(3):58; doi: 10.3390/medsci6030058
MaherTM, OballaE, SimpsonJK, et al.An epithelial biomarker signature for idiopathic pulmonary fibrosis: An analysis from the multicentre PROFILE cohort study. Lancet Respir Med, 2017; 5(12):946–955; doi: 10.1016/S2213-2600(17)30430-7
35.
MilaraJ, NavarroR, JuanG, et al.Sphingosine-1-Phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition. Thorax, 2012; 67(2):147–156; doi: 10.1136/thoraxjnl-2011-200026
36.
NambiarS, Bong HowS, GummerJ, et al.Metabolomics in chronic lung diseases. Respirology, 2020; 25(2):139–148; doi: 10.1111/resp.13530
37.
NambiarS, ClynickB, HowBS, et al.There is detectable variation in the lipidomic profile between stable and progressive patients with Idiopathic Pulmonary Fibrosis (IPF). Respir Res, 2021a;22(1):105; doi: 10.1186/s12931-021-01682-3
38.
NambiarS, TanDBA, ClynickB, et al.Untargeted metabolomics of human plasma reveal lipid markers unique to chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Proteomics Clin Appl, 2021b;15(2–3):e2000039; doi: 10.1002/prca.202000039
39.
NewtonDA, LottesRG, RyanRM, et al.Dysfunctional lactate metabolism in human alveolar type II cells from idiopathic pulmonary fibrosis lung explant tissue. Respir Res, 2021; 22(1):278; doi: 10.1186/s12931-021-01866-x
40.
PardoA, SelmanM. The interplay of the genetic architecture, aging, and environmental factors in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol, 2021; 64(2):163–172; doi: 10.1165/rcmb.2020-0373PS
41.
RastogiS, MishraSS, AroraMK, et al.Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment. Pharmacol Ther, 2023; 250:108519; doi: 10.1016/j.pharmthera.2023.108519
42.
RindlisbacherB, SchmidC, GeiserT, et al.Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis—a potential biomarker role for LysoPC. Respir Res, 2018; 19(1):7; doi: 10.1186/s12931-018-0714-2
43.
RindlisbacherB, StrebelC, GulerS, et al.Exhaled breath condensate as a potential biomarker tool for idiopathic pulmonary Fibrosis-a pilot study. J Breath Res, 2017; 12(1):16003; doi: 10.1088/1752-7163/aa840a
44.
RoqueW, RomeroF. Cellular metabolomics of pulmonary fibrosis, from amino acids to lipids. Am J Physiol Cell Physiol, 2021; 320(5):C689–C695; doi: 10.1152/ajpcell.00586.2020
45.
SchraufnagelDE. The health effects of ultrafine particles. Exp Mol Med, 2020; 52(3):311–317; doi: 10.1038/s12276-020-0403-3
46.
SeeligerB, CarleoA, Wendel-GarciaPD, et al.Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication. Front Pharmacol, 2022; 13:837680; doi: 10.3389/fphar.2022.837680
47.
SenguptaA, WeljieAM. NMR spectroscopy-based metabolic profiling of biospecimens. Curr Protoc Protein Sci, 2019; 98(1):e98; doi: 10.1002/cpps.98
48.
ShiX, ChenY, ShiM, et al.The novel molecular mechanism of pulmonary fibrosis: Insight into lipid metabolism from reanalysis of single-cell RNA-Seq databases. Lipids Health Dis, 2024; 23(1):98; doi: 10.1186/s12944-024-02062-8
49.
SinghP, GuinD, PattnaikB, et al.Mapping the genetic architecture of idiopathic pulmonary fibrosis: Meta-analysis and epidemiological evidence of case-control studies. Gene, 2024; 895:147993; doi: 10.1016/j.gene.2023.147993
50.
SofiaM, ManiscalcoM, de LaurentiisG, et al.Exploring airway diseases by NMR-Based metabonomics: A review of application to exhaled breath condensate. J Biomed Biotechnol, 2011; 2011:403260; doi: 10.1155/2011/403260
51.
StrambuIR, SeemayerCA, FagardLM-CA, et al.GLPG1205 for idiopathic pulmonary fibrosis: A phase 2 randomised placebo-controlled trial. Eur Respir J, 2023; 61(3):2201794; doi: 10.1183/13993003.01794-2022
52.
SummerR, ToddJL, NeelyML, et al.Circulating metabolic profile in idiopathic pulmonary fibrosis: Data from the IPF-PRO registry. Respir Res, 2024; 25(1):58; doi: 10.1186/s12931-023-02644-7
53.
SuryadevaraV, RamchandranR, KampDW, et al.Lipid mediators regulate pulmonary fibrosis: Potential mechanisms and signaling pathways. Int J Mol Sci, 2020; 21(12):4257; doi: 10.3390/ijms21124257
54.
TaddeiML, GiannoniE, RaugeiG, et al.Mitochondrial oxidative stress due to complex I Dysfunction promotes fibroblast activation and melanoma cell invasiveness. J Signal Transduct, 2012; 2012:684592; doi: 10.1155/2012/684592
55.
WangS, LiangY, DaiC. Metabolic regulation of fibroblast activation and proliferation during organ fibrosis. Kidney Dis (Basel, Switzerland), 2022; 8(2):115–125; doi: 10.1159/000522417
56.
WoltersPJ, CollardHR, JonesKD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol, 2014; 9:157–179; doi: 10.1146/annurev-pathol-012513-104706
57.
XueC, WuN, FanY, et al.Distinct metabolic features in the plasma of patients with silicosis and dust-exposed workers in China: A case-control study. BMC Pulm Med, 2021; 21(1):91; doi: 10.1186/s12890-021-01462-1
58.
YalnızE, PolatG, DemirciF, et al.Are idiopathic pulmonary fibrosis patients more anxious and depressive than patient’s with other interstitial lung disease? Sarcoidosis Vasc Diffuse Lung Dis, 2019; 36(4):294–301; doi: 10.36141/svdld.v36i4.8418
59.
YanF, WenZ, WangR, et al.Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by lipidomics. BMC Pulm Med, 2017; 17(1):174; doi: 10.1186/s12890-017-0513-4
60.
YanP, LiuJ, LiZ, et al.Glycolysis reprogramming in idiopathic pulmonary fibrosis: Unveiling the mystery of lactate in the lung. Int J Mol Sci, 2023; 25(1):315; doi: 10.3390/ijms25010315
61.
YuB, ZanettiKA, TemprosaM, et al.The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 prospective cohort studies. Am J Epidemiol, 2019; 188(6):991–1012; doi: 10.1093/aje/kwz028
62.
ZankDC, BuenoM, MoraAL, et al.Idiopathic pulmonary fibrosis: Aging, mitochondrial dysfunction, and cellular bioenergetics. Front Med (Lausanne), 2018; 5:10; doi: 10.3389/fmed.2018.00010
63.
ZhaoW, BaiB, LiH, et al.The role of oxidative stress-related genes in idiopathic pulmonary fibrosis. Sci Rep, 2025; 15(1):5954; doi: 10.1038/s41598-025-89770-y
64.
ZhaoYD, YinL, ArcherS, et al.Metabolic heterogeneity of idiopathic pulmonary fibrosis: A metabolomic study. BMJ Open Respir Res, 2017; 4(1):e000183; doi: 10.1136/bmjresp-2017-000183
